News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,318 Results
Type
Article (42481)
Company Profile (294)
Press Release (675543)
Multimedia
Podcasts (79)
Webinars (12)
Section
Business (210445)
Career Advice (2091)
Deals (36630)
Drug Delivery (107)
Drug Development (83055)
Employer Resources (175)
FDA (16575)
Job Trends (15409)
News (356054)
Policy (33921)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (89)
Alliances (51432)
ALS (92)
Alzheimer's disease (1396)
Antibody-drug conjugate (ADC) (132)
Approvals (16580)
Artificial intelligence (266)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (188)
Bladder cancer (77)
Brain cancer (29)
Breast cancer (281)
Cancer (2286)
Cardiovascular disease (182)
Career advice (1751)
Career pathing (31)
CAR-T (152)
Cell therapy (427)
Cervical cancer (19)
Clinical research (67520)
Collaboration (855)
Compensation (530)
Complete response letters (25)
COVID-19 (2660)
CRISPR (45)
C-suite (247)
Cystic fibrosis (103)
Data (2207)
Decentralized trials (2)
Denatured (28)
Depression (45)
Diabetes (272)
Diagnostics (6452)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (111)
Drug shortages (28)
Duchenne muscular dystrophy (94)
Earnings (88259)
Editorial (38)
Employer branding (21)
Employer resources (149)
Events (115213)
Executive appointments (733)
FDA (17837)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (757)
Gene editing (110)
Generative AI (21)
Gene therapy (316)
GLP-1 (745)
Government (4537)
Grass and pollen (5)
Guidances (55)
Healthcare (18998)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (124)
Indications (30)
Infectious disease (2803)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (322)
IPO (16785)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (10)
Labor market (38)
Layoffs (488)
Leadership (17)
Legal (8379)
Liver cancer (76)
Lung cancer (322)
Lymphoma (155)
Machine learning (7)
Management (59)
Manufacturing (317)
MASH (68)
Medical device (13459)
Medtech (13464)
Mergers & acquisitions (20383)
Metabolic disorders (702)
Multiple sclerosis (79)
NASH (17)
Neurodegenerative disease (93)
Neuropsychiatric disorders (29)
Neuroscience (1949)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Northern California (2674)
Now hiring (39)
Obesity (376)
Opinion (229)
Ovarian cancer (76)
Pain (94)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (237)
Patient recruitment (109)
Peanut (49)
People (59269)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20941)
Phase II (29705)
Phase III (22265)
Pipeline (1191)
Policy (150)
Postmarket research (2654)
Preclinical (8921)
Press Release (68)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (396)
Real estate (6258)
Recruiting (67)
Regulatory (23133)
Reports (46)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (55)
Southern California (2297)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3725)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (41)
The Weekly (49)
United States (23171)
Vaccines (704)
Venture capitalists (41)
Weight loss (250)
Women's health (35)
Worklife (15)
Date
Today (198)
Last 7 days (887)
Last 30 days (2759)
Last 365 days (33403)
2025 (10657)
2024 (35770)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (53)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (40721)
Australia (6521)
California (6113)
Canada (2016)
China (536)
Colorado (268)
Connecticut (273)
Delaware (149)
Europe (86926)
Florida (907)
Georgia (204)
Idaho (57)
Illinois (542)
India (26)
Indiana (315)
Iowa (11)
Japan (163)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4596)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1729)
New Mexico (29)
New York (1738)
North Carolina (981)
North Dakota (8)
Northern California (2674)
Ohio (202)
Oklahoma (14)
Oregon (39)
Pennsylvania (1379)
Puerto Rico (12)
Rhode Island (33)
South America (1162)
South Carolina (22)
South Dakota (1)
Southern California (2297)
Tennessee (101)
Texas (909)
Utah (182)
Virginia (152)
Washington D.C. (61)
Washington State (558)
West Virginia (3)
Wisconsin (56)
718,318 Results for "satsuma pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
May 1, 2025
·
9 min read
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 66th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.
June 13, 2024
·
6 min read
Press Releases
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
November 26, 2024
·
5 min read
Press Releases
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
October 31, 2024
·
5 min read
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
October 8, 2024
·
8 min read
Deals
SNBL to Acquire Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.
April 16, 2023
·
10 min read
Biotech Bay
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
Satsuma Pharmaceuticals, Inc . today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting.
April 21, 2023
·
4 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
Biotech Bay
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) today announced that John Kollins, President and Chief Executive Officer, will deliver a company presentation during the SVB Securities Global Biopharma Conference, which is being held virtually February 14-16.
February 2, 2023
·
2 min read
Business
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full-year 2022 and summarized recent business highlights.
March 28, 2023
·
12 min read
1 of 71,832
Next
